HRP20231367T1 - Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima - Google Patents
Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima Download PDFInfo
- Publication number
- HRP20231367T1 HRP20231367T1 HRP20231367TT HRP20231367T HRP20231367T1 HR P20231367 T1 HRP20231367 T1 HR P20231367T1 HR P20231367T T HRP20231367T T HR P20231367TT HR P20231367 T HRP20231367 T HR P20231367T HR P20231367 T1 HRP20231367 T1 HR P20231367T1
- Authority
- HR
- Croatia
- Prior art keywords
- ligand
- inhibitor
- subject
- polymorphism
- seq
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title claims 3
- 238000000034 method Methods 0.000 title claims 3
- 102000004634 CD30 Ligand Human genes 0.000 claims 23
- 108010017987 CD30 Ligand Proteins 0.000 claims 23
- 239000003112 inhibitor Substances 0.000 claims 22
- 230000000694 effects Effects 0.000 claims 11
- 108700028369 Alleles Proteins 0.000 claims 6
- 208000011231 Crohn disease Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 238000011272 standard treatment Methods 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
- 229960004914 vedolizumab Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Inhibitor CD30 liganda za uporabu u postupku liječenja najmanje jedne od upalne bolesti, fibrostenotičke bolesti, i fibrotičke bolesti, pomoću inhibiranja ili reduciranja aktivnosti ili ekspresije CD30 liganda kod subjekta, naznačeno time što postupak sadrži:
a) odabir subjekta koji ima, ili se sumnja da ima, najmanje jednu od upalne bolesti, fibrostenotičke bolesti, i fibrotičke bolesti;
b) identificiranje subjekta kao nosioca genotipa koji sadrži polimorfizam na najmanje jednom od rs911605 i rs1006026; i
c) primjenu subjektu efikasne količine inhibitora CD30 liganda kako bi se inhibirala ili reducirala aktivnost ili ekspresija CD30 liganda kod subjekta.
2. Inhibitor CD30 liganda za uporabu u skladu sa patentnim zahtjevom 1, naznačeno time što polimorfizam na rs911605 sadrži "A" alel na nukleobazi 501 unutar rs911605 (SEQ ID NO: 1), i pri čemu polimorfizam na rs 1006026 sadrži "G" alel na nukleobazi 501 unutar rs1006026 (SEQ ID NO: 3).
3. Inhibitor CD30 liganda za uporabu u skladu sa patentnim zahtjevom 1, naznačeno time što genotip sadrži polimorfizam na rs911605 i polimorfizam na rs 1006026.
4. Inhibitor CD30 liganda za uporabu u skladu sa patentnim zahtjevom 3, naznačeno time što polimorfizam na rs911605 sadrži "A" alel na nukleobazi 501 unutar rs911605 (SEQ ID NO: 1), i polimorfizam na rs1006026 sadrži "G" alel na nukleobazi 501 unutar rs1006026 (SEQ ID NO: 3).
5. Inhibitor CD30 liganda za uporabu u skladu sa patentnim zahtjevom 1, naznačeno time što identificiranje subjekta kao nosioca genotipa sadrži:
a) dovođenje u kontakt uzorka koji je dobiven od subjekta koji sadrži genetički materijal sa sekvencom nukleinske kiseline sposobnom za hibridizaciju sa najmanje 10 susjednih nukleobaza između nukleobaze 400 i nukleobaze 600 najmanje jedne od SEQ ID NO: 1 i SEQ ID NO: 3 pod standardnim uvjetima hibridizacije, pri čemu najmanje 10 susjednih nukleobaza sadrži nukleobazu na poziciji 501 iz najmanje jedne od SEQ ID NO: 1 i SEQ ID NO: 3; i
b) detektiranje vezivanja između sekvence nukleinske kiseline i najmanje 10 susjednih nukleobaza između nukleobaze 400 i nukleobaze 600 najmanje jedne od SEQ ID NO: 1 i SEQ ID NO: 2.
6. Inhibitor CD30 liganda za uporabu u skladu sa patentnim zahtjevom 1, naznačeno time što je inhibitor CD30 liganda antitijelo ili antigen-vezujući fragment koji ciljno djeluje na CD30 ligand ili CD30, ili njihovu kombinaciju.
7. Inhibitor CD30 liganda za uporabu u skladu sa patentnim zahtjevom 1, naznačeno time što dodatno sadrži primjenu subjektu efikasne količine inhibitora člana 15 superobitelji liganda faktora nekroze tumora (TL1A).
8. Inhibitor CD30 liganda za uporabu u skladu sa patentnim zahtjevom 7, naznačeno time što je inhibitor TL1A antagonist antitijelo ili antigen-vezujući fragment koji ciljno djeluje na TL1A.
9. Inhibitor aktivnosti ili ekspresije CD30 liganda za uporabu u postupku liječenja umjerene do teške Kronove bolesti kod subjekta, naznačeno time što postupak sadrži:
a) identificiranje subjekta sa Kronovom bolešću (CD) kao nosioca genotipa koji sadrži polimorfizam najmanje jedan od rs911605 i rs 1006026, genotipa koji je povezan sa rizikom da će subjekt razviti umjereni do teški oblik CD koja sadrži opstruktivnu CD; i
b) primjenu subjektu terapijski efikasne količine inhibitora aktivnosti ili ekspresije CD30 liganda.
10. Inhibitor aktivnosti ili ekspresije CD30 liganda za uporabu u skladu sa patentnim zahtjevom 9, naznačeno time što dodatno sadrži određivanje da li subjekt ima ili će razviti najmanje jedno od izostanka odgovora ili gubitka odgovora na standardno liječenje.
11. Inhibitor aktivnosti ili ekspresije CD30 liganda za uporabu u skladu sa patentnim zahtjevom 10, naznačeno time što je standardno liječenje odabrano iz grupe koja se sastoji od glukokortikosteroida, anti-TNF terapije, anti-a4-b7 terapije (vedolizumab), anti-IL12p40 terapije (ustekinumab), talidomida, i citoksina.
12. Inhibitor aktivnosti ili ekspresije CD30 liganda za uporabu u skladu sa patentnim zahtjevom 9, naznačeno time što polimorfizam na rs911605 sadrži "A" alel na nukleobazi 501 unutar rs911605 (SEQ ID NO: 1), i pri čemu polimorfizam na rs1006026 sadrži "G" alel na nukleobazi 501 unutar rs1006026 (SEQ ID NO: 3).
13. Inhibitor aktivnosti ili ekspresije CD30 liganda za uporabu u skladu sa patentnim zahtjevom 12, naznačeno time što genotip sadrži polimorfizam na rs911605 i polimorfizam na rs1006026.
14. Inhibitor aktivnosti ili ekspresije CD30 liganda za uporabu u skladu sa patentnim zahtjevom 9, naznačeno time što je inhibitor aktivnosti CD30 liganda antitijelo ili antigen-vezujući fragment koji ciljno djeluje na CD30 ligand ili CD30, ili njihovu kombinaciju.
15. Inhibitor aktivnosti ili ekspresije CD30 liganda za uporabu u skladu sa patentnim zahtjevom 9, naznačeno time što dodatno sadrži primjenu subjektu efikasne količine inhibitora člana 15 superobitelji liganda faktora nekroze tumora (TL1A).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664720P | 2018-04-30 | 2018-04-30 | |
| US201862681557P | 2018-06-06 | 2018-06-06 | |
| US201862784179P | 2018-12-21 | 2018-12-21 | |
| PCT/US2019/029402 WO2019212899A1 (en) | 2018-04-30 | 2019-04-26 | Methods and systems for selection and treatment of patients with inflammatory diseases |
| EP19796203.8A EP3774897B1 (en) | 2018-04-30 | 2019-04-26 | Methods and systems for selection and treatment of patients with inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231367T1 true HRP20231367T1 (hr) | 2024-02-16 |
Family
ID=68386125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231367TT HRP20231367T1 (hr) | 2018-04-30 | 2019-04-26 | Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20210238684A1 (hr) |
| EP (2) | EP3774897B1 (hr) |
| JP (1) | JP2021532060A (hr) |
| KR (1) | KR20210013062A (hr) |
| CN (1) | CN112368301A (hr) |
| AU (1) | AU2019261933A1 (hr) |
| CA (1) | CA3098720A1 (hr) |
| DK (1) | DK3774897T3 (hr) |
| ES (1) | ES2962715T3 (hr) |
| FI (1) | FI3774897T3 (hr) |
| HR (1) | HRP20231367T1 (hr) |
| HU (1) | HUE063908T2 (hr) |
| LT (1) | LT3774897T (hr) |
| MA (1) | MA52251A (hr) |
| MD (1) | MD3774897T2 (hr) |
| PL (1) | PL3774897T3 (hr) |
| PT (1) | PT3774897T (hr) |
| RS (1) | RS64747B1 (hr) |
| SI (1) | SI3774897T1 (hr) |
| TW (1) | TW202003573A (hr) |
| WO (1) | WO2019212899A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024509746A (ja) * | 2021-02-17 | 2024-03-05 | プロメテウス バイオサイエンシーズ，インク． | 抗ｃｄ３０ｌ抗体およびその使用 |
| WO2024026386A1 (en) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibody formulations |
| WO2024026395A1 (en) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2011020906A2 (en) * | 2009-08-21 | 2011-02-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT |
| KR101932697B1 (ko) * | 2012-04-27 | 2019-03-21 | 노보 노르디스크 에이/에스 | 사람 cd30 리간드 항원 결합 단백질 |
| EP3659598A1 (en) * | 2012-06-04 | 2020-06-03 | Gaurav Agrawal | Compositions and methods for treating crohn's disease and related conditions and infections |
| CN110121509B (zh) * | 2016-10-26 | 2024-05-07 | 西达-赛奈医疗中心 | 中和抗tl1a单克隆抗体 |
-
2019
- 2019-04-26 DK DK19796203.8T patent/DK3774897T3/da active
- 2019-04-26 HR HRP20231367TT patent/HRP20231367T1/hr unknown
- 2019-04-26 CA CA3098720A patent/CA3098720A1/en active Pending
- 2019-04-26 EP EP19796203.8A patent/EP3774897B1/en active Active
- 2019-04-26 EP EP23192639.5A patent/EP4296285A3/en active Pending
- 2019-04-26 AU AU2019261933A patent/AU2019261933A1/en active Pending
- 2019-04-26 WO PCT/US2019/029402 patent/WO2019212899A1/en active Application Filing
- 2019-04-26 MA MA052251A patent/MA52251A/fr unknown
- 2019-04-26 MD MDE20210158T patent/MD3774897T2/ro unknown
- 2019-04-26 SI SI201930656T patent/SI3774897T1/sl unknown
- 2019-04-26 PT PT197962038T patent/PT3774897T/pt unknown
- 2019-04-26 KR KR1020207033851A patent/KR20210013062A/ko not_active Application Discontinuation
- 2019-04-26 RS RS20231000A patent/RS64747B1/sr unknown
- 2019-04-26 PL PL19796203.8T patent/PL3774897T3/pl unknown
- 2019-04-26 CN CN201980044299.1A patent/CN112368301A/zh active Pending
- 2019-04-26 JP JP2020560463A patent/JP2021532060A/ja active Pending
- 2019-04-26 ES ES19796203T patent/ES2962715T3/es active Active
- 2019-04-26 LT LTEPPCT/US2019/029402T patent/LT3774897T/lt unknown
- 2019-04-26 HU HUE19796203A patent/HUE063908T2/hu unknown
- 2019-04-26 FI FIEP19796203.8T patent/FI3774897T3/fi active
- 2019-04-26 US US17/051,731 patent/US20210238684A1/en active Pending
- 2019-04-30 TW TW108115107A patent/TW202003573A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3774897T3 (fi) | 2023-11-03 |
| HUE063908T2 (hu) | 2024-02-28 |
| MA52251A (fr) | 2021-02-17 |
| RS64747B1 (sr) | 2023-11-30 |
| US20210238684A1 (en) | 2021-08-05 |
| AU2019261933A1 (en) | 2020-12-03 |
| TW202003573A (zh) | 2020-01-16 |
| JP2021532060A (ja) | 2021-11-25 |
| EP3774897A1 (en) | 2021-02-17 |
| PL3774897T3 (pl) | 2024-01-29 |
| SI3774897T1 (sl) | 2024-01-31 |
| CN112368301A (zh) | 2021-02-12 |
| KR20210013062A (ko) | 2021-02-03 |
| EP3774897B1 (en) | 2023-09-27 |
| EP4296285A2 (en) | 2023-12-27 |
| LT3774897T (lt) | 2023-11-10 |
| ES2962715T3 (es) | 2024-03-20 |
| DK3774897T3 (da) | 2023-11-06 |
| EP4296285A3 (en) | 2024-02-28 |
| PT3774897T (pt) | 2023-11-10 |
| WO2019212899A1 (en) | 2019-11-07 |
| MD3774897T2 (ro) | 2024-02-29 |
| CA3098720A1 (en) | 2019-11-07 |
| EP3774897A4 (en) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231367T1 (hr) | Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima | |
| AU2016281772B2 (en) | Detection of chromosome interactions | |
| CN107109494B (zh) | Il-33介导型疾病的治疗方法和诊断方法 | |
| EP2944961A1 (en) | Markers for cancer prognosis and therapy and methods of use | |
| Tako et al. | Transcriptomic analysis of the host response to Giardia duodenalis infection reveals redundant mechanisms for parasite control | |
| Bandoh et al. | Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma | |
| US10337004B2 (en) | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide | |
| WO2019153656A1 (zh) | piRNA-54265在结直肠癌的诊治和预后评价方面的应用 | |
| CN109890982A (zh) | 通过nrf2及其下游目标基因的表达状态和突变状态诊断和治疗癌症的方法 | |
| Mallikarjunappa et al. | Uncovering quantitative trait loci associated with resistance to Mycobacterium avium ssp. paratuberculosis infection in Holstein cattle using a high-density single nucleotide polymorphism panel | |
| Shalini et al. | Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India | |
| JP2016520289A5 (hr) | ||
| Urabe et al. | Genetic polymorphisms of IL-17F and TRAF3IP2 could be predictive factors of the long-term effect of infliximab against Crohn’s disease | |
| Lurje et al. | Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma | |
| Pagan et al. | Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma | |
| US20220252603A1 (en) | Method for treating cancer patients using c-met inhibitor | |
| KR20210033402A (ko) | Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법 | |
| Persson et al. | Autotomy behavior correlates with the DRG and spinal expression of sodium channels in inbred mouse strains | |
| Ozguler et al. | Recent insights into the management of Behçet syndrome | |
| JPWO2019212899A5 (hr) | ||
| RU2019122099A (ru) | Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile | |
| JP2020502179A5 (hr) | ||
| Paramarta et al. | OP0156 Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-Of-Concept Study with Nilotinib A Tyrosine Kinase Inhibitor | |
| KR102164432B1 (ko) | Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법 | |
| Meehan et al. | PWE-347 Adherent, invasive mucosa-associated e. coli isolates from colorectal cancer patients activate WNT signalling |